Efficacy of pembrolizumab (pembro) monotherapy versus chemotherapy for PD-L1-positive (CPS ≥10) advanced G/GEJ cancer in the phase II KEYNOTE-059 (cohort 1) and phase III KEYNOTE-061 and KEYNOTE-062 studies

被引：0
|
作者：
Wainberg, Zev A.
Fuchs, Charles S.
Tabernero, Josep
Shitara, Kohei
Muro, Kei
Van Cutsem, Eric
Bang, Yung-Jue
Chung, Hyun Cheol
Yamaguchi, Kensei
Varga, Eniko
Chen, Jen-Shi
Hochhauser, Daniel
Thuss-Patience, Peter C.
Al-Batran, Salah-Eddin
Garrido, Marcelo
Kher, Uma
Shih, Chie-Schin
Shah, Sukrut
Bhagia, Pooja
Chao, Joseph
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA
[2] Smilow Canc Hosp, Yale Canc Ctr, New Haven, CT USA
[3] Vall dHebron Univ Hosp, Barcelona, Spain
[4] Vall dHebron Inst Oncol, Barcelona, Spain
[5] Natl Canc Ctr Hosp East, Chiba, Japan
[6] Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan
[7] Univ Hosp, Leuven, Belgium
[8] Katholieke Univ Leuven, Leuven, Belgium
[9] Seoul Natl Univ Hosp, Seoul, South Korea
[10] Yonsei Univ, Coll Med, Yonsei Canc Ctr, Seoul, South Korea
[11] JFCR, Canc Inst Hosp, Tokyo, Japan
[12] Debreceni Egyet Klin Kozpont, Debrecen, Hungary
[13] Linkou Chang Gung Mem Hosp, Taoyuan, Taiwan
[14] UCL Hosp NHS Fdn Trust, London, England
[15] Charite Campus Virchow Klinikum, Berlin, Germany
[16] Inst Klin Onkol, Frankfurt, Germany
[17] Pontificia Univ Catolica Chile, Santiago, Chile
[18] Merck & Co Inc, Kenilworth, NJ USA
[19] City Hope Comprehens Canc Ctr, Duarte, CA USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
427
引用
收藏
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab plus chemotherapy for advanced G/GEJ adenocarcinoma (GC): The phase III KEYNOTE-062 study
    Chung, H. C.
    Bang, Y-J.
    Tabernero, J.
    Van Cutsem, E.
    Fuchs, C. S.
    Wyrwicz, L.
    Lee, K-W.
    Kudaba, I.
    Garrido, M.
    Castro, H.
    Mansoor, W.
    Braghiroli, M. I.
    Goekkurt, E.
    Chao, J.
    Wainberg, Z. A.
    Kher, U.
    Shah, S.
    Shitara, K.
    ANNALS OF ONCOLOGY, 2019, 30
  • [2] KEYNOTE-059 cohort 3: safety and efficacy of pembrolizumab monotherapy for first-line treatment of patients (pts) with PD-L1-positive advanced gastric/gastroesophageal (G/GEJ) cancer
    Daniel, Catenacci, V
    Zev, Wainberg
    Charles, Fuchs S.
    Marcelo, Garrido
    Bang Yung-Jue
    Kei, Muro
    Mary, Savage
    Wang Jiangdian
    Minori, Koshiji
    Rita, Dalal P.
    Yoon-Koo, Kang
    ANNALS OF ONCOLOGY, 2017, 28
  • [3] KEYNOTE-059 cohort 1: Efficacy and safety of pembrolizumab (pembro) monotherapy in patients with previously treated advanced gastric cancer.
    Fuchs, Charles S.
    Doi, Toshihiko
    Jang, Raymond Woo -Jun
    Muro, Kei
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia Ibrahim
    Shah, Manish A.
    Metges, Jean -Philippe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V. T.
    Bang, Yung-Jue
    Wang, Jiangdian
    Koshiji, Minori
    Dalai, Rita P.
    Yoon, Harry H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [4] Pembrolizumab with or without chemotherapy versus chemotherapy for advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The phase III KEYNOTE-062 study.
    Tabernero, Josep
    Van Cutsem, Eric
    Bang, Yung-Jue
    Fuchs, Charles S.
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol
    Salguero, Hugo Raul Castro
    Mansoor, Wasat
    Braghiroli, Maria Ignez Freitas Melro
    Goekkurt, Eray
    Chao, Joseph
    Wainberg, Zev A.
    Kher, Uma
    Shah, Sukrut
    Kang, SoonMo Peter
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (18)
  • [5] Pembrolizumab with or without chemotherapy versus chemotherapy alone for patients with PD-L1-positive advanced gastric or gastroesophageal junction adenocarcinoma: Update from the phase 3 KEYNOTE-062 trial
    Wainberg, Zev A.
    Shitara, Kohei
    Van Cutsem, Eric
    Wyrwicz, Lucjan
    Lee, Keun Wook
    Kudaba, Iveta
    Garrido, Marcelo
    Chung, Hyun Cheol Cheol
    Lee, Jeeyun
    Castro-Salguero, Hugo Raul
    Mansoor, Wasat
    Braghiroli, Maria Ignez
    Karaseva, Nina
    Goekkurt, Eray
    Satake, Hironaga
    Chao, Joseph
    Kher, Uma
    Shah, Sukrut
    Bhagia, Pooja
    Tabernero, Josep
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (04)
  • [6] KEYNOTE-059 cohort 1: Pembrolizumab (Pembro) monotherapy in previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer in patients (Pts) with PD-L1+tumors-Asian subgroup analysis.
    Muro, Kei
    Fuchs, Charles S.
    Jang, Raymond Woo-Jun
    Satoh, Taroh
    Machado, Manuela
    Sun, Weijing
    Jalal, Shadia Ibrahim
    Shah, Manish A.
    Metges, Jean-Philippe
    Garrido, Marcelo
    Golan, Talia
    Mandala, Mario
    Wainberg, Zev A.
    Catenacci, Daniel V. T.
    Bang, Yung-Jue
    Lin, Jianxin
    Lu, Jia
    Yoon, Harry H.
    Doi, Toshihiko
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (04)
  • [7] Pembrolizumab versus paclitaxel for previously treated patients with PD-L1-positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter C.
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [8] Pembrolizumab (pembro) vs paclitaxel (PTX) for previously treated advanced gastric or gastroesophageal junction (G/GEJ) cancer: Phase 3 KEYNOTE-061 trial.
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun Cheol
    Muro, Kei
    Goekkurt, Eray
    Mansoor, Wasat
    McDermott, Raymond S.
    Shacham-Shmueli, Einat
    Chen, Xinqun
    Kang, S. Peter
    Mayo, Carlos Alberto
    Ohtsu, Atsushi
    Shitara, Kohei
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [9] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Fuchs, Charles S.
    Ozguroglu, Mustafa
    Bang, Yung-Jue
    Di Bartolomeo, Maria
    Mandala, Mario
    Ryu, Min-Hee
    Fornaro, Lorenzo
    Olesinski, Tomasz
    Caglevic, Christian
    Chung, Hyun C.
    Muro, Kei
    Van Cutsem, Eric
    Elme, Anneli
    Thuss-Patience, Peter
    Chau, Ian
    Ohtsu, Atsushi
    Bhagia, Pooja
    Wang, Anran
    Shih, Chie-Schin
    Shitara, Kohei
    GASTRIC CANCER, 2022, 25 (01) : 197 - 206
  • [10] Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial
    Charles S. Fuchs
    Mustafa Özgüroğlu
    Yung-Jue Bang
    Maria Di Bartolomeo
    Mario Mandala
    Min-Hee Ryu
    Lorenzo Fornaro
    Tomasz Olesinski
    Christian Caglevic
    Hyun C. Chung
    Kei Muro
    Eric Van Cutsem
    Anneli Elme
    Peter Thuss-Patience
    Ian Chau
    Atsushi Ohtsu
    Pooja Bhagia
    Anran Wang
    Chie-Schin Shih
    Kohei Shitara
    Gastric Cancer, 2022, 25 : 197 - 206
12345